NanoString Technologies

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The Company's nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business. The system is positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

Company Growth (employees)
Type
Public
HQ
Seattle, US
Founded
2003
Size (employees)
407 (est)
NanoString Technologies was founded in 2003 and is headquartered in Seattle, US

Key People/Management at NanoString Technologies

Brad Gray

Brad Gray

President and Chief Executive Officer
James Johnson

James Johnson

CFO
William Young

William Young

Executive Chairman of the Board
Wayne Burns

Wayne Burns

Senior Vice President, Operations & Administration

NanoString Technologies Office Locations

NanoString Technologies has offices in Seattle and Hong Kong
Seattle, US (HQ)
2000 530 Fairview Ave N

NanoString Technologies Financials and Metrics

NanoString Technologies Financials

NanoString Technologies's revenue was reported to be $18.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

18.1 m

Net income (Q1, 2017)

(18.9 m)

EBIT (Q1, 2017)

(17.5 m)

Market capitalization (17-Oct-2017)

235.6 m

Cash (31-Mar-2017)

5.4 m
NanoString Technologies's current market capitalization is $235.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

31.4 m47.6 m62.7 m86.5 m

Revenue growth, %

52%32%38%

Cost of goods sold

15 m

Gross profit

16.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

10.9 m12.3 m11.6 m13.1 m15.7 m14.7 m22.6 m23.9 m18.1 m

R&D expense

5.3 m6 m5.9 m5.8 m5.8 m7.2 m8.8 m8.7 m10.8 m

General and administrative expense

12.9 m12.5 m14.1 m12.8 m12 m14.9 m15.5 m15.6 m17.6 m

Operating expense total

18.2 m18.5 m20 m18.6 m17.8 m22.1 m24.3 m24.3 m28.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.9 m17.2 m21.9 m20.6 m

Accounts Receivable

8.3 m12.4 m19.7 m22.2 m

Inventories

6.8 m5.4 m3.9 m13.8 m

Current Assets

60.7 m95.3 m82.8 m113.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

21.2 m18.8 m14.3 m15.7 m16.6 m29.6 m19.3 m10.5 m5.4 m

Accounts Receivable

9.1 m15.3 m10.5 m13.2 m12.9 m15.5 m25.2 m21 m16.7 m

Inventories

6.4 m5.8 m7.9 m9.4 m11.7 m11.8 m12.5 m11.7 m14.5 m

Current Assets

99.1 m92.9 m79.3 m81.5 m74.6 m87.2 m98.5 m90.7 m92.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(29.3 m)(50 m)(45.6 m)(47.1 m)

Depreciation and Amortization

1.8 m1.5 m2.4 m3 m

Accounts Receivable

(5 m)(4.1 m)(7.3 m)(2.5 m)

Inventories

(1.4 m)(1.3 m)(5.4 m)(5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(14.1 m)(12.1 m)(14.9 m)(12.4 m)(9.5 m)(14.6 m)(10.8 m)(10.1 m)(18.9 m)

Accounts Receivable

9.1 m15.3 m10.5 m13.2 m12.9 m15.5 m25.2 m21 m16.7 m

Inventories

6.4 m5.8 m7.9 m9.4 m11.7 m11.8 m12.5 m11.7 m14.5 m

Accounts Payable

2.7 m2.2 m4.6 m2.4 m2.6 m3.5 m4 m2.1 m2.1 m
USDY, 2017

Revenue/Employee

44.4 k

Financial Leverage

-34.8 x
Show all financial metrics

NanoString Technologies Market Value History

Traffic Overview of NanoString Technologies

NanoString Technologies Online and Social Media Presence

NanoString Technologies Company Life and Culture

You may also be interested in